Per today's Chairman's blog: "Amarantus Diagno
Post# of 30028
"Amarantus Diagnostics, is ready to have a major impact in the field of biomarkers to diagnose Alzheimer’s disease, and potentially monitor drug response"
Does this mean LymPro, potentially, will be able to gauge various drugs' efficacy for curing Alzheimer's disease alongside diagnosing it too? Is that really what that statement is saying? I didn't know this before. If I'm correct, that would add a lot more value to the assay than I originally had thought. I've completely focused on its diagnosing ability.